[Special Stock] Vibozone Pharm Rises on Approval News of Non-Narcotic Painkiller

Non-narcotic analgesic 'Eonapraju' (generic name Opiranjelin) has been approved as the 38th new drug, sending Bivobon Pharmaceutical's stock soaring to the upper limit.

원본보기 아이콘

As of 9:18 AM on the 13th, Bivobon Pharmaceutical is trading at 11,310 KRW, up 30% (2,610 KRW) from the previous trading day. The stock price of Bivobon Pharmaceutical rose to the price limit as soon as the market opened.

This is interpreted as a result of the news that Eonapraju, developed by Bivobon Pharmaceutical, has been approved as a new drug. On the same day, Bivobon Pharmaceutical announced that the non-narcotic analgesic Eonapraju (generic name Opiranjelin) had obtained marketing authorization from the Ministry of Food and Drug Safety.

This drug is used as a short-term therapy for moderate to severe acute pain control in adults after surgery. Opiranjelin is a non-narcotic analgesic in injectable form used to relieve postoperative pain. It produces analgesic effects by simultaneously inhibiting glycine transporter type 2 (GlyT2) and serotonin receptor 2a (5HT2a), which are directly involved in the generation of pain signals in peripheral nociceptors such as skin, muscles, ligaments, and joints.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.